Sugi Predict

Sugi Predict / Compounds / SCHEMBL1289972

SCHEMBL1289972

SCHEMBL1289972

CCOC(=O)c1cc(C2CC2)c2c(C)c(-c3ccc(C(N)=O)cc3)c(F)cn2c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.36
▸ GLA P06280 4/20 0.36
▸ GAA P10253 4/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 3/20 0.36
▸ DYRK1A Q13627 1/20 0.35
▸ FDFT1 P37268 1/20 0.35
▸ BRD4 O60885 1/20 0.33
▸ BRD9 Q9H8M2 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ GNRHR P30968 1/20 0.33
▸ ADRB2 P07550 1/20 0.33
▸ SSTR5 P35346 1/20 0.33
▸ TP53 P04637 2/20 0.33
▸ POLB P06746 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1289979 0.91 GAA (0.39) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL12501961 0.90 KDM4E (0.38) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL1290217 0.88 BRD4 (0.36) BRD4BRD9SCN9A
SCHEMBL1290104 0.88 KDM4E (0.36) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL12502207 0.87 CDK5 (0.42) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL1290154 0.87 ELANE (0.36) KDM4EGLAGAAALDH1A1HPGD
Potassium Ion SCHEMBL1290123 0.86 BRD4 (0.35) BRD4BRD9SCN9A
SCHEMBL12502390 0.85 ALOX5AP (0.38) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL1290073 0.85 SMN1; SMN2 (0.42) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL20083157 0.83 SCN9A (0.34) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3476844-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2019-05-01 — — EP disclosed
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2019-04-11 — — US disclosed
US-10155021-B2 Antimicrobial 4-oxoquinolizines EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) 2018-12-18 — — US disclosed
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2018-10-18 — — US disclosed
EP-2621491-B1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EMERGENT PRODUCT DEV GAITHERSBURG INC (US) 2018-08-29 — — EP disclosed
EP-3312176-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES Emergent Product Development Gaithersburg Inc. (US) 2018-04-25 — — EP disclosed
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2017-08-17 — — US disclosed
US-20170209437-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2017-07-27 — — US disclosed
US-20170209437-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2017-07-27 — — US disclosed
US-20170209437-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2017-07-27 — — US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 — — US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 — — US disclosed
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2013-09-19 — — US disclosed
EP-2621491-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS Evolva SA (CH) 2013-08-07 — — EP disclosed
EP-2621925-A1 FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN Merck Sharp & Dohme Corp. (US) 2013-08-07 — — EP disclosed
WO-2012104305-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES EVOLVA SA (CH) 2012-08-09 — — WO disclosed
WO-2012047570-A1 FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN SCHERING CORPORATION (US) 2012-04-12 — — WO disclosed
WO-2012047487-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS EVOLVA SA (CH) 2012-04-12 — — WO disclosed
EP-1542989-A1 PROTEIN TYROSINE KINASE INHIBITORS Danter, Wayne R. (CA) 2005-06-22 — — EP disclosed
WO-2004011456-A1 PROTEIN TYROSINE KINASE INHIBITORS DANTER WAYNE R (CA) 2004-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190105367-A1 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B KDM4E 555/4885GLA 4236/4885GAA 2095/4885
US-10155021-B2 Antimicrobial 4-oxoquinolizines DCAF15, CUL4A, CUL4B KDM4E 518/4885GLA 4199/4885GAA 2043/4885
US-20180296555-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B KDM4E 1923/4885GLA 1521/4885GAA 2833/4885
US-20170232060-A9 ANTIMICROBIAL 4-OXOQUINOLIZINES CUL4A, DCAF15, CUL4B KDM4E 555/4885GLA 4236/4885GAA 2095/4885
US-20130245035-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B KDM4E 2480/4885GLA 1497/4885GAA 2757/4885
US-20170209437-A1 2-PYRIDONE ANTIMICROBIAL COMPOSITIONS TOP2A, TOP1, TOP2B KDM4E 1923/4885GLA 1521/4885GAA 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.